B-Flexion Life Sciences-backed healthcare companies Paratek Pharmaceuticals and Radius Health Inc have completed their merger, creating a combined entity with a diversified portfolio spanning infectious disease, podiatry, and endocrinology. The transaction, advised by law firm Mintz, secured $1.3 billion in financing through B-Flexion capital and debt from Blackstone Credit & Insurance, Sixth Street, Oaktree Capital, Silver Point Capital, and Pharmakon Advisors. Paratek, headquartered in Boston and King of Prussia, Pennsylvania, brings assets like Nuzyra and Xhance, while Radius, based in Boston, contributes Tymlos, a key osteoporosis therapy.

The merged company projects $1 billion in annual revenue by 2026, leveraging synergies from Paratek’s operational excellence and Radius’s scientific innovation.